Risk factors
Ironwood Pharmaceuticals (IRWD) risk factors
Item 1A of every Ironwood Pharmaceuticals Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors46 risks12 new9 dropped14 reworded
Linzess is subject to Medicare price negotiations setting a net price of $136 effective January 1, 2027. Apraglutide development and VectivBio integration carry significant regulatory and operational execution risks. Indebtedness stands at $585.0 million with $215.5 million in cash.
Filed Feb 26, 2026 - FY2024 10-K risk factors43 risks
Heavy commercial reliance on LINZESS partnered with AbbVie. Integration risks and debt from the VectivBio acquisition of apraglutide. Stringent pricing, reimbursement, and healthcare reform pressures.
Filed Mar 31, 2025